Search the Newsreel

HCM|HUTCHMED (China) Ltd|Price:12.180|Chg%:+0.020

HCM IV Acquisition Corp. (HACQ) logs Q2 income but flags going concern risk

HCM IV Acquisition Corp. (HACQ) reported a net income of $1.89 million for Q2 2026, primarily due to interest earned on its Trust Account investments. However, the SPAC faces a significant going concern risk, as highlighted by management, due to limited cash outside the …

HCM IV Acquisition Corp. Q2 2026: Net income $1.89M, EPS $0.05— 10-Q Summary

HCM IV Acquisition Corp. (HACQ) reported a net income of $1.89 million and diluted EPS of $0.05 for Q2 2026. For the six months ended June 30, 2026, the company posted a net loss of $1.06 million and a diluted loss per share of …

Half Year 2026 HUTCHMED (China) Ltd Earnings Call Transcript

This document contains the Half Year 2026 earnings call transcript for HUTCHMED (China) Ltd, held on July 30, 2026. Key points highlight strong China product sales and global growth for fruquintinib, alongside two new drug approvals. However, R&D expenses increased, other ventures revenue declined, …

HCM IV Acquisition Ord Shs Class A (HACQ) Stock News Today

HCM IV Acquisition Ord Shs Class A (HACQ) Earnings Forecast: Future EPS & Revenue Growth Estimates

HCM|HUTCHMED (China) Ltd|Price:11.550|Chg%:+0.420

This article provides a detailed overview of HUTCHMED (China) Ltd (HCM) stock performance, financial indicators, and analyst ratings. It highlights the company's current market trends, key figures, and an analyst consensus of "Buy" with a significant upside potential. The company's business segments in Oncology …

HCM Stock Price and Chart — NASDAQ:HCM

This

Earnings call transcript: HUTCHMED posts solid H1 2026 growth, stock edges up

HUTCHMED reported strong H1 2026 results, with total revenue reaching $278 million and oncology sales up 23% to $162 million, driven by demand for its cancer drugs. The company maintained profitability despite increased R&D spending and ended the period with $1.4 billion in cash. …

HUTCHMED’s FRUZAQLA approved or launched in 41 countries

HUTCHMED reported its 2026 interim results, showing total revenue broadly unchanged at $278.3 million and net income of $15.9 million. Oncology product in-market sales increased significantly, with FRUZAQLA global sales reaching $185.4 million due to strong ex-US growth and launches/approvals in 41 countries. The …

HUTCHMED (NASDAQ:HCM) Announces Earnings Results

HUTCHMED (China) Ltd (HCM) (H1 2026) Earnings Call Highlights: Strong Product Sales Growth and New Approvals Drive Profitability

HUTCHMED (China) Ltd reported strong product sales growth and new drug approvals in H1 2026, leading to continued profitability with a net income of $60 million and a $1.4 billion cash reserve. The company is advancing its novel ATTC pipeline with two first-in-class assets …

Hutchmed returns to revenue growth in first half of 2026

Hutchmed (HCM.US; 0013.HK) reported a slight revenue increase in the first half of 2026, driven by double-digit growth in its oncology and immunology drugs which offset declines in other ventures. While revenue rose by 0.2% to $278.3 million, net income significantly dropped to $15.9 …

HUTCHMED Limited Reports Earnings Results for the Half Year Ended June 30, 2026

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) Receives Average Rating of "Hold" from Brokerages

HUTCHMED (China) Limited Sponsored ADR (NASDAQ:HCM) has received an average "Hold" rating from six brokerages, with an average 12-month price target of $14.87. Recent analyst actions were mixed, including Goldman Sachs cutting its target to $14 (neutral) and Bank of America lowering its target …

HUTCHMED (China) 1H Rev $278.3M >HCM

This article reports that HUTCHMED (China) achieved a revenue of $278.3 million in the first half of the year. The company's stock symbol is HCM.

HUTCHMED Number of Employees 2026 | Employee Count & Headcount Data

HUTCHMED (China) Ltd. has a global workforce of 1,789 employees as of March 2026, marking a 1.2% decline since 2023. The company is actively hiring, with 5 job postings in 2026, though hiring velocity has slowed significantly. Its workforce is concentrated in China, and …

REG - Hutchmed China Ltd - HUTCHMED Reports 2026 Interim Results

HUTCHMED (China) Limited reported its 2026 interim financial results, highlighting a strong recovery in China product sales for ELUNATE® and SULANDA® with over 40% growth each, alongside a significant expansion of FRUZAQLA® sales ex-US. The company maintained profitability while increasing R&D investment, focusing on …

HUTCHMED (China) Limited 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:HCM) 2026-07-30

HCM IV Acquisition Corp. Revenue Breakdown – NASDAQ:HACQ

HUTCHMED (China) Ltd (HCM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of HUTCHMED (China) Ltd (HCM), detailing its support, resistance, indicators, and moving averages as of July 27, 2026. It presents a summary of various technical indicators like MACD, RSI, and KDJ, alongside moving average data, offering a "Neutral" …

HUTCHMED (China) Ltd (HCM) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides an overview of HUTCHMED (China) Ltd (HCM) stock, focusing on its dividend and stock split history. It notes that no dividend data is available for the past five years. The page also includes current stock performance metrics and market capitalization for …

HCM IV Acquisition Ord Shs Class A (HACQ) Balance Sheet

HUTCHMED (China) Ltd (HCM) Cash Flow

The article provides a detailed cash flow statement for HUTCHMED (China) Ltd (HCM), presenting both annual and quarterly data. It covers operating, investing, and financing cash flows, along with free cash flow, to help evaluate the company's financial health. The data includes year-over-year percentage …

HCM IV Acquisition Ord Shs Class A (HACQ) Risk Assessment: Volatility, Financial Risk & Investment Risk

HUTCHMED (China) Ltd (HCM) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for HUTCHMED (China) Ltd (HCM), focusing on its P/E, P/B, and Fair Value. However, the relevant data for P/E, P/B, P/S, and P/CF ratios have not been disclosed by the company yet, suggesting that a comprehensive valuation is …

HCM|HUTCHMED (China) Ltd|Price:11.010|Chg%:+0.050

This article provides an analysis of HUTCHMED (China) Ltd (HCM) through TradingKey's stock scoring system, although no stock score is currently available due to insufficient data. It details the methodologies behind generating various scores such as financial health, company valuation, earnings forecasts, price momentum, …

HACQ|HCM IV Acquisition Ord Shs Class A|Price:10.070|

This article provides a detailed profile of HCM IV Acquisition Corp. (HACQ), a blank check company. It outlines the company's purpose to pursue a merger or acquisition with technology and software infrastructure firms targeting financial services, real estate, and asset management industries. The profile …

HUTCHMED (China) Ltd (HCM) Financial Health: Profitability & Balance Sheet Analysis

This article provides an analysis of HUTCHMED (China) Ltd's (HCM) financial health, focusing on its profitability and balance sheet. It includes real-time stock quotes, market capitalization, and P/E ratio, indicating a slight positive movement in its stock price. The content seems to be a …

HUTCHMED (China) Ltd (HCM) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for HUTCHMED (China) Ltd (HCM), including analyst ratings and price targets. Based on 10 analysts, the stock has a strong buy trend with a target price of USD 21.071, indicating a 92.25% upside. The current stock price is …

HUTCHMED (China) Ltd HCM Income Statement

This article provides a detailed historical income statement for HUTCHMED (China) Ltd (HCM), including quarterly and annual figures from FY2012H1 through FY2024H2. It covers key financial metrics like total revenue, operating expenses, R&D expenses, operating profit, and net income, alongside their year-over-year percentage changes. …

Goldman Sachs Maintains Hutchmed (China)(HCM.US) With Hold Rating, Cuts Target Price to $14

Goldman Sachs has reiterated its Hold rating on Hutchmed (China) (HCM.US) but has reduced the target price for the stock to $14. This adjustment reflects Goldman Sachs's updated outlook for the pharmaceutical company.

HUTCHMED (HCM) Projected to Release Earnings on Thursday